Analysts Raise Price Targets Following Strong Data From Revolution Medicines’ Pancreatic Cancer Drug

Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data. Latest Ratings for RVMD Date Firm Action From To Mar 2022 Stifel Upgrades Hold Buy Nov 2021 HC Wainwright & Co. Maintains Buy Sep 2021 Stifel Initiates Coverage On Hold View More Analyst Ratings for…

Read More